Mingyuan Medicare (233 HK, HK$1.26)-waiting for consolidation
Friday, June 12, 2009 at 9:32AM
Newsflow. MY announced that it has a co-operation agreement with Chinese National Human Genome Center in Shanghai (CHGC) and Shanghai Biochip Co. (SBC) for development and production of diagnositc kits for detecting Influenza A viruses. Two types of diagnostic kits has been developed and are now waiting for SFDA approval.
Our view. We think MY has taken good step to diversified to different areas by: 1) acquire 75% of Shanghai Kang Pei for developing Health Check business in China in Jan 2009; 2) acuire 95% of Genetal in May for developing HPV DNA testing kit for cervical cancer in May 2009; 3) co-operate with CHGC and SBC for Influenza A testing kit. However, we think that the new business would not make significant contribution for the company in the short term and MY need time to consolidate the new business as well. The counter is now trading at 22.5x FY12/09F and 19.4x FY12/10F P/E based on market consensus.

Reader Comments